Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Income Statement Analysis

See more : Immo Moury SCA (IMMOU.BR) Income Statement Analysis – Financial Results

Complete financial analysis of Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Recordati Industria Chimica e Farmaceutica S.p.A., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Velan Inc. (VLN.TO) Income Statement Analysis – Financial Results
Freetech Road Recycling Technology (Holdings) Limited (6888.HK) Income Statement Analysis – Financial Results
Iwatani Corporation (8088.T) Income Statement Analysis – Financial Results
Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ) Income Statement Analysis – Financial Results
Sundaram Multi Pap Limited (SUNDARAM.BO) Income Statement Analysis – Financial Results

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.recordati.com

About Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	2.08B	1.85B	1.58B	1.45B	1.48B	1.35B	1.29B	1.15B	1.05B	987.36M	941.63M	828.32M	762.04M	728.13M	747.52M	689.63M	628.44M	576.19M	576.08M	488.31M	487.54M
Cost of Revenue	600.76M	566.74M	427.73M	406.83M	436.90M	395.57M	382.75M	360.96M	335.21M	327.05M	327.33M	293.56M	259.98M	240.07M	235.62M	222.20M	206.35M	192.01M	200.62M	179.27M	199.75M
Gross Profit	1.48B	1.29B	1.15B	1.04B	1.04B	956.67M	905.37M	792.98M	712.47M	660.30M	614.30M	534.76M	502.06M	488.07M	511.90M	467.44M	422.09M	384.18M	375.46M	309.03M	287.79M
Gross Profit Ratio	71.15%	69.42%	72.93%	71.92%	70.52%	70.75%	70.29%	68.72%	68.00%	66.88%	65.24%	64.56%	65.88%	67.03%	68.48%	67.78%	67.16%	66.68%	65.17%	63.29%	59.03%
Research & Development	255.75M	220.10M	166.14M	146.24M	129.68M	109.69M	100.26M	83.71M	76.74M	85.27M	74.73M	63.41M	55.96M	68.84M	69.45M	58.86M	49.12M	45.40M	44.96M	37.31M	32.77M
General & Administrative	128.25M	109.49M	84.50M	72.79M	72.78M	67.72M	65.58M	64.78M	58.98M	57.17M	54.09M	45.49M	45.39M	44.03M	43.72M	39.37M	33.93M	27.17M	25.30M	21.84M	21.13M
Selling & Marketing	472.86M	462.67M	396.39M	349.07M	372.80M	333.50M	330.79M	304.44M	293.20M	282.95M	275.19M	250.57M	232.16M	216.48M	223.72M	214.25M	202.04M	191.13M	192.34M	156.00M	148.03M
SG&A	601.11M	572.16M	480.89M	421.86M	445.59M	401.22M	396.38M	369.22M	352.18M	340.12M	329.28M	296.05M	277.55M	260.50M	267.44M	253.62M	235.97M	218.29M	217.64M	177.84M	169.17M
Other Expenses	66.71M	497.00K	-652.00K	1.71M	-2.54M	-841.00K	-1.46M	181.00K	-1.32M	26.00K	-1.06M	-1.35M	-2.41M	0.00	-3.75M	0.00	0.00	-2.16M	0.00	1.11M	-36.15M
Operating Expenses	923.56M	792.26M	647.03M	568.09M	575.27M	510.91M	496.63M	452.93M	428.92M	425.39M	404.01M	352.21M	338.58M	333.29M	349.70M	322.71M	290.59M	263.83M	264.33M	218.61M	206.76M
Cost & Expenses	1.52B	1.36B	1.07B	974.92M	1.01B	906.48M	879.39M	813.89M	764.13M	752.44M	731.34M	645.77M	598.56M	573.35M	585.32M	544.90M	496.94M	455.85M	464.95M	397.88M	406.51M
Interest Income	-402.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-520.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	74.46M	34.45M	20.90M	17.48M	20.10M	22.28M	13.53M	11.57M	12.24M	16.63M	10.23M	6.78M	5.07M	3.79M	5.80M	6.58M	4.07M	2.16M	4.13M	4.81M	6.45M
Depreciation & Amortization	142.67M	125.76M	97.59M	93.67M	78.25M	56.86M	48.15M	37.93M	38.48M	42.79M	34.71M	24.75M	24.27M	26.95M	34.81M	29.44M	25.97M	23.31M	22.06M	21.14M	26.74M
EBITDA	708.16M	559.35M	596.31M	566.83M	544.36M	501.50M	456.66M	377.71M	321.76M	277.30M	244.49M	191.87M	187.74M	181.73M	193.27M	174.17M	157.47M	143.65M	133.19M	115.19M	71.63M
EBITDA Ratio	34.01%	33.41%	37.74%	39.58%	36.74%	36.96%	35.06%	32.90%	30.53%	28.17%	25.44%	24.88%	24.64%	24.96%	25.85%	25.26%	25.06%	24.93%	23.12%	23.07%	14.69%
Operating Income	558.01M	437.33M	490.19M	469.02M	465.27M	442.22M	406.49M	327.42M	278.52M	231.03M	195.42M	166.96M	163.48M	154.78M	162.20M	144.73M	131.50M	120.34M	111.13M	90.43M	81.03M
Operating Income Ratio	26.80%	23.60%	31.02%	32.37%	31.40%	32.70%	31.56%	28.37%	26.58%	23.40%	20.75%	20.16%	21.45%	21.26%	21.70%	20.99%	20.92%	20.89%	19.29%	18.52%	16.62%
Total Other Income/Expenses	-66.97M	-35.89M	-26.84M	-13.36M	-21.12M	-24.28M	-17.38M	-10.14M	-13.08M	-16.26M	-14.63M	-14.44M	-3.47M	-3.79M	-9.55M	-6.58M	-4.07M	-2.16M	-4.13M	-15.00K	-42.60M
Income Before Tax	491.04M	401.44M	463.35M	455.66M	444.14M	417.94M	389.12M	317.28M	265.44M	214.78M	180.80M	160.34M	160.01M	151.00M	152.65M	138.15M	127.43M	118.18M	107.00M	86.72M	38.44M
Income Before Tax Ratio	23.58%	21.66%	29.32%	31.45%	29.97%	30.91%	30.21%	27.50%	25.34%	21.75%	19.20%	19.36%	21.00%	20.74%	20.42%	20.03%	20.28%	20.51%	18.57%	17.76%	7.88%
Income Tax Expense	101.82M	89.10M	77.38M	100.63M	75.28M	105.51M	100.32M	79.85M	66.63M	53.58M	47.10M	41.84M	43.57M	42.42M	42.09M	37.72M	42.56M	44.15M	38.44M	32.76M	14.69M
Net Income	389.21M	312.34M	385.97M	354.98M	368.83M	312.38M	288.76M	237.41M	198.79M	161.19M	133.68M	118.48M	116.43M	108.57M	110.56M	100.42M	84.87M	74.03M	64.54M	53.13M	23.75M
Net Income Ratio	18.69%	16.85%	24.43%	24.50%	24.89%	23.10%	22.42%	20.57%	18.97%	16.33%	14.20%	14.30%	15.28%	14.91%	14.79%	14.56%	13.50%	12.85%	11.20%	10.88%	4.87%
EPS	1.86	1.52	1.87	1.73	1.80	1.53	1.40	1.15	0.97	0.79	0.66	0.59	0.58	0.55	0.56	0.51	0.43	0.37	0.33	0.27	0.12
EPS Diluted	1.86	1.49	1.85	1.70	1.76	1.49	1.38	1.14	0.95	0.77	0.63	0.56	0.56	0.52	0.54	0.50	0.42	0.36	0.31	0.26	0.12
Weighted Avg Shares Out	209.14M	205.58M	206.01M	205.76M	204.96M	204.38M	207.03M	206.12M	205.27M	203.57M	201.59M	199.72M	199.37M	198.17M	197.22M	196.67M	198.56M	200.05M	198.05M	196.49M	195.60M
Weighted Avg Shares Out (Dil)	209.14M	209.06M	209.08M	209.06M	209.08M	209.09M	209.10M	209.17M	209.03M	209.06M	211.85M	211.58M	209.41M	198.17M	204.36M	196.67M	203.51M	206.21M	205.55M	204.35M	200.40M

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2024 Earnings Call Transcript

November 8, 2024seekingalpha.com

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RCDTF) Q3 2024 Earnings Conference Call November 8, 2024 10:00 AM ET Company Participants Eugenia Litz - VP & Head, Investor Relations Robert Koremans - CEO & Director Luigi Corte - Group CFO &...

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q2 2023 Earnings Call Transcript

July 28, 2023seekingalpha.com

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q2 2023 Earnings Call Transcript

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q1 2023 Earnings Call Transcript

May 14, 2023seekingalpha.com

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RCDTF) Q1 2023 Earnings Conference Call May 11, 2023 10:00 AM ET Company Participants Federica De Medici – Director Investor Relations & Corporate Communications Rob Koremans – Chief Executive Officer Luigi La Corte –...

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q4 2022 Earnings Call Transcript

February 25, 2023seekingalpha.com

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RCDTF) Q4 2022 Earnings Conference Call February 21, 2023 10:00 AM ET Company Participants Andrea Recordati - Chairman Rob Koremans - Chief Executive Officer Luigi La Corte - Group Chief Financial Officer Alberto Martinez...

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q3 2022 Earnings Call Transcript

November 12, 2022seekingalpha.com

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RCDTF) Q3 2022 Earnings Conference Call November 8, 2022 10:00 AM ET Company Participants Federica De Medici - Investor Relations & Corporate Communications Robert Koremans - Chief Executive Officer Luigi La Corte - Chief...

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q2 2022 Results - Earnings Call Transcript

July 30, 2022seekingalpha.com

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RCDTF) Q2 2022 Results Conference Call July 28, 2022 10:00 AM ET Company Participants Federica De Medici - Investor Relations & Corporate Communications Robert Koremans - Chief Executive Officer Luigi La Corte - Chief...

Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) CEO Robert Koremans on Q1 2022 Results - Earnings Call Transcript

May 14, 2022seekingalpha.com

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCPK:RCDTF) Q1 2022 Results Conference Call May 10, 2022 10:00 AM ET Company Participants Federica De Medici - Investor Relations & Corporate Communications Robert Koremans - Chief Executive Officer Luigi La Corte - Chief...